Resource type:
Advocacy and policy
Link:
This post hoc analysis of the SELECTION trial evaluates baseline factors predicting sustained corticosteroid-free remission in ulcerative colitis (UC) patients treated with filgotinib, a JAK-1 inhibitor. Using data from 173 patients receiving corticosteroids at maintenance baseline, the study found that remission was more likely in biologic-naive patients, current smokers, females, and those with lower endoscopic disease activity. These findings help refine patient profiles most likely to benefit from filgotinib and inform personalized UC treatment strategies.
Photo Credit: Canva